Alamar Biosciences, Inc.NASDAQ: ALMR

Alamar Biosciences to Participate in Upcoming Investor Conferences

· Issued by Alamar Biosciences, Inc. via GlobeNewswire

Summary by 6ix AI

Alamar Biosciences, Inc., a proteomics company that develops technology to detect proteins in blood, will take part in two investor conferences: the UBS Global Healthcare Conference and Citi's 2026 Global Healthcare Conference.

Key details

  • At the UBS Global Healthcare Conference in Palm Beach Gardens, FL, Alamar will hold a fireside chat on Tuesday, November 10 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.
  • At Citi's 2026 Global Healthcare Conference in Miami, FL, Alamar will hold investor meetings on Wednesday, December 2.
  • A live and archived webcast of the session will be available in the Investors section of the company website at investors.alamarbio.com.

6ix AI wrote this summary from the release below and checked it against the release.

Fremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the following investor conferences:

  • UBS Global Healthcare Conference in Palm Beach Gardens, FL

Fireside chat on Tuesday, November 10 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time

  • Citi’s 2026 Global Healthcare Conference in Miami, FL

Investor meetings on Wednesday, December 2

Interested parties may access a live and archived webcast of the session on the “Investors” section of the company website at investors.alamarbio.com.

About Alamar Biosciences, Inc.

Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.

View original source (GlobeNewswire)Alamar Biosciences, Inc. on 6ix

Story so far

Earlier from Alamar Biosciences

Later from Alamar Biosciences

All Alamar Biosciences news releases